AI医疗股美股盘前大涨, Recursion Pharmaceuticals, Inc.(RXRX)涨12%, CRISPR Therapeutics AG( CRSP)涨近3%, Tempus AI ( TEM)涨超3%, Beam Therapeutics, Inc.(BEAM)涨7%。
近期,“木头姐”带领她的ARK研究团队发布了名为《Big Ideas 2025》的报告,长达148页,深入探讨了当今不断发展的五个技术创新平台——AI、机器人技术、能源存储、公共区块链和多组学测序(Multiomic Sequencing)之间的复杂融合,并指出这些颠覆性技术会推动各行业实现指数级增长,助力全球经济的阶跃变化。
其中,在多组学测序方面,报告指出,在海量多组学数据的支持下,结合可编程生物学的驱动,运行自主实验室的AI系统可能会显著降低药物研发全流程的成本,从而改变这个长期停滞的制药行业的回报状况。
在AI技术支持下,多组学技术能够通过生成数据、运行测试、推断和决策,以及运行实验来推断和指导开发,从而经济有效地解决小疾病人群的问题,并更精准地识别患者和疾病;并将药物上市时间从13年缩短到8年,总成本降低4倍。
当前,木头姐的Ark Invest的投资组合中的AI医药股包括RXRX、CRSP、TEM、TWST和BEAM等前景看好的医疗保健股票。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.